Showing results (161-170 of 258) with videos related to
Sort By:
Pageof 26
Pharmacogenomics|November 15, 2012
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group studyNikitas Nikitas, Alexandra Karadimou, Eliza Tsitoura, et al.Anticancer Research|October 3, 2014
Docetaxel and intermittent erlotinib in patients with metastatic Non-Small Cell Lung Cancer; a phase II study from the Hellenic Cooperative Oncology GroupVasilios Karavasilis, Paris Kosmidis, Konstantinos N Syrigos, et al.Cancer Genomics & Proteomics|February 20, 2021
Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast CancerAliki Ntzifa, Areti Strati, Georgia-Angeliki Koliou, et al.Plos One|June 27, 2014
In situ quantitative measurement of HER2mRNA predicts benefit from trastuzumab-containing chemotherapy in a cohort of metastatic breast cancer patientsMaria Vassilakopoulou, Taiwo Togun, Urania Dafni, et al.Anticancer Research|January 25, 2008
Evaluation of the prognostic role of a panel of biomarkers in stage IB-IIIA non-small cell lung cancer patientsEleni Timotheadou, Dimosthenis-Vasilios Skarlos, Epaminondas Samantas, et al.The New England Journal of Medicine|February 17, 2006
Prognostic significance of autoimmunity during treatment of melanoma with interferonHelen Gogas, John Ioannovich, Urania Dafni, et al.Journal of Translational Medicine|November 4, 2010
Evaluation of six CTLA-4 polymorphisms in high-risk melanoma patients receiving adjuvant interferon therapy in the He13A/98 multicenter trialHelen Gogas, Urania Dafni, Henry Koon, et al.Molecular and Clinical Oncology|February 20, 2016
Lessons from the past: Long-term safety and survival outcomes of a prematurely terminated randomized controlled trial on prophylactic vs. hemoglobin-based administration of erythropoiesis-stimulating agents in patients with chemotherapy-induced anemiaGiannis Mountzios, Gerasimos Aravantinos, Zoi Alexopoulou, et al.Clinical Colorectal Cancer|December 26, 2015
Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant OxaliplatinStacey A Cohen, Chen Wu, Ming Yu, et al.Anticancer Research|November 27, 2008
Myelotoxicity as a prognostic factor in patients with advanced breast cancer treated with chemotherapy: a pooled analysis of two randomised trials conducted by the Hellenic Cooperative Oncology GroupAngelos K Koutras, George Fountzilas, Urania Dafni, et al.Pageof 26